If you wish to obtain access to one of the following
cell lines, please print out, complete and sign this agreement form and return
to Steve Cobbold or Herman Waldmann at Therapeutic
Immunology Group, Sir William Dunn School of Pathology, South Parks Road,
Oxford OX1 3RE, UK
FAX:
44-(0)1865-275501 Email:
stephen.cobbold@path.ox.ac.uk
I/we wish to have access to the
following monoclonal antibody producing cell lines:
(a) YTS 191.1.2 anti-mouse CD4 (L3/T4 epitope a) Rat IgG2b Depleting
in vivo
(b) YTS 169.4.2.1 anti-mouse CD8 alpha (Lyt-2) Rat
IgG2b Depleting in vivo
(c) YTA 3.1.2 anti-mouse CD4 (L3/T4 epitope
b) Rat IgG2b Synergistic depletion with (a)
(d) YTS 156.7.7 anti-mouse CD8 alpha/beta (Lyt-3) Rat IgG2b Synergistic
depletion with (b)
(e) YTS 154.7.7.10 anti-mouse Thy-1 (monomorphic) Rat IgG2b Depleting
in vivo
(f) YTS 121.5.2 anti-mouse CD5 (Lyt-1) Rat
IgG2b Depleting in vivo
(g) YTS 177.9.6.1 anti-mouse CD4 (L3/T4 epitope a) Rat IgG2a Non-depleting
(blocking) in vivo
(h) YTS 105.18.10 anti-mouse CD8 alpha (Lyt-2) Rat
IgG2a Very little depletion in
vivo
(i) YGITR
765.4.2 anti-mouse GITR (TNSFR18) Rat IgG2b Agonistic antibody
(j) YGL 386.2.2 anti-mouse GITRL (TNSF18) Rat
IgG1 Blocking
mAb
(k) YTH
655 anti-human CD2 Rat IgG2b Depletion of hCD2+ cells
in vivo
(l) Other (please identify)
..........................................................................................................................................
(please delete those not
applicable)
1) The abovementioned cell lines and
any product or cell derived from them shall remain at all times the property of
Prof. Herman Waldmann and Dr. Stephen Cobbold.
2) The above mentioned cell lines and
any product derived from them will not be used in any form of commercial
exploitation.
3) Any publication arising from the
use of these cell lines or antibodies should quote Cobbold
S. et al (1984) Nature 312, 548 (a)(b); Qin S. et al
(1987) Eur. J. Immunol. 17, 1159 (c)(d); Cobbold S.
& H. Waldmann (1986) Transplantation 41, 634 (e)(f); Qin S. et
al (1990) Eur. J. Immunol. 20, 2737 (g)(h); Tone, M. et al (2003)
Proc. Natl. Acad. Sci. USA. 100 (25): 15059-15064(i)(j); Kendal AR. et al. J. Exp Med. 2011(k); or other appropriate original
references (l).
4) Prof. Herman Waldmann and Dr. Stephen Cobbold accept no responsibility for the condition of the
cell lines nor any liability nor responsibility associated with the use or
misuse of the cell lines nor any product derived from them.
5) The abovementioned cell lines and any product or cell
derived from them may be distributed to third parties only if these conditions
are applied to said third parties who should also sign and return a copy of
this form to Steve Cobbold or Herman Waldmann at the
above address.
I agree to all the above conditions of use and
acceptance of the above named hybrid myeloma cell lines/antibodies.
Signed
...................................................................... Date....................................................................
In the case that the cells are being passed to a third
party:
I received these hybrid myeloma cell lines/antibodies
from: ...........................................................................
Please note that we reserve the right not to
acknowledge any request and not to supply cells reagents or information
requested by this form. We would appreciate any application via this form to be
sent together with a cover letter that clearly explains the proposed usage of
any material that we might supply together with evidence that the applicant is
a bone fide and recognized member of a non-commercial academic institution.
This file is
http://users.path.ox.ac.uk/~scobbold/tig/mabreq.html last updated Steve Cobbold 1/9/2011.